Tenaya reports Q2 2026 results with new TN-201, TN-401 data and Alnylam upfront payment

Tenaya Therapeutics disclosed second-quarter 2026 financial results and a pipeline update on August 5, 2026. In June 2026, the company shared new safety and efficacy data from the ongoing MyPEAK-1 Phase 1b/2 clinical trial of TN-201 in adults with MYBPC3-associated HCM, reflecting 78-104 weeks of follow-up for three patients at the 3E13 vg/kg dose and 26-52 weeks of follow-up for four patients at the 6E13 vg/kg dose.¹ As of the May 2026 cutoff, all six evaluable patients achieved reductions in one or more echocardiographic measures of hypertrophy and all six achieved improvements in one or more measurements of symptom burden, as measured by NYHA classification or KCCQ.¹ TN-201 was generally well tolerated across both dose cohorts, with no dose-limiting toxicities observed, and all patients have tapered off immunosuppressive medicines.¹

For TN-401, data presented at the ASGCT Annual Meeting from the RIDGE-1 trial covered three patients dosed at 3E13 vg/kg with follow-up ranging from Week 32-52 and three patients dosed at 6E13 vg/kg with 20-32 weeks of follow-up.¹ PVC count decreased in all patients by a mean of 64% from baseline,¹ and two patients with high baseline NSVT rates saw substantial reductions as early as Week 20.¹ TN-401 was generally well tolerated at both doses with no dose-limiting toxicities, and all patients had tapered off immunosuppressives as of the April 2026 data cut.¹

Both programs hold EMA PRIME designation, and Tenaya said it is pursuing alignment with regulators on late-stage pivotal trial plans for TN-201 and TN-401, with updates expected in the fourth quarter of 2026.¹ TN-301 is targeted to begin a Phase 2 proof-of-activity trial in the second half of 2027.¹

On finances, Tenaya received a $10.0 million upfront payment from Alnylam in April 2026 under a collaboration eligible for up to $1.1 billion in milestones plus research cost reimbursement.¹ Cash and cash equivalents were $78.1 million as of June 30, 2026, which the company said is sufficient to fund operations through the third quarter of 2027.¹